Biblio Discovery — Demo Discovery Service

4 results for "Samuel Short"

Showing 1–4 · 0.40 seconds · RSS

  1. Journal Article Full text

    Acute kidney injury in patients treated with immune checkpoint inhibitors

    Shruti Gupta; Samuel Short; Meghan E. Sise et al.

    Journal for ImmunoTherapy of Cancer · 2021 · English · OpenAlex Scopus

    BACKGROUND: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. METHODS: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI…

  2. Journal Article

    AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

    Shruti Gupta; Steven G. Coca; Lili Chan et al.

    Journal of the American Society of Nephrology · 2020 · English · OpenAlex Scopus

    Significance Statement Although AKI is an important sequela of coronavirus disease 2019 (COVID-19), data on AKI treated with RRT (AKI-RRT) in patients with COVID-19 are limited. In a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67…

  3. Journal Article Full text

    Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

    Shruti Gupta; Salim S. Hayek; Wei Wang et al.

    JAMA Internal Medicine · 2020 · English · OpenAlex Scopus

    Importance: The US is currently an epicenter of the coronavirus disease 2019 (COVID-19) pandemic, yet few national data are available on patient characteristics, treatment, and outcomes of critical illness from COVID-19. Objectives: To assess factors associated with death and to examine…

  4. Journal Article Full text

    Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

    Shruti Gupta; Wei Wang; Salim S. Hayek et al.

    JAMA Internal Medicine · 2020 · English · OpenAlex Scopus

    Importance: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness…